Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Join Us at SMi’s Superbugs & Superdrugs Conference USA

by Global Biodefense Staff
November 8, 2018
White Blood Cells Interacting with MRSA

The issue of antibacterial resistance is becoming increasingly prevalent within the world of modern medicine. Difficult-to-treat pathogens create an incredibly real issue within clinical environments; and the problem needs to be addressed with novel treatments and the development of mechanisms which circumvent current therapeutic barriers. The push to commercialization of novel anti-infectives is also a big barrier to market entry within the field; with red-tape and funding restrictions creating hindrances to the progress of anti-infective drugs through trial and regulatory approvals processes.

If you have not yet confirmed your attendance there is still time to secure one of the last few remaining seats at the only antibacterial event dedicated to combating drug resistance. With our Superbugs portfolio of events firmly becoming established as the industry’s leading platform for updates on clinical progress, networking and industry developments, don’t miss the chance to book your place before registration closes.

SPECIAL PRICE FOR WORKSHOP & CONFERENCE – THIS WEEK ONLY!

Join the workshops for only $499!
Attend the conference for only $1099!

PROGRAM HIGHLIGHTS

  • DISCOVERY AND EVALUATION OF INHIBITORS OF INTERMEDIARY METABOLISM AS NOVEL ANTIBIOTICS AGAINST GRAM-NEGATIVE BACTERIAL PATHOGENS, Brent Cezairliyan, Senior Scientist, Octagon Therapeutics
  • TP-6076: A NOVEL FLUOROCYCLINE ANTIBIOTIC WITH POTENT ACTIVITY AGAINST CARBAPENEM-RESISTANT GRAM (-) ORGANISMS, Joe Newman, Senior Director, Head of Biology, Tetraphase Pharmaceuticals
  • THE MICROBIOME AND ITS IMPACT ON THE FIELD, Christopher Ford, Group Leader, Microbiome Sciences of ID, Seres Therapeutics
  • PRACTICAL CLINICAL DIAGNOSTIC APPLICATIONS USING LASER LIGHT-SCATTERING: UTILITY, ADOPTION, AND OPPORTUNITIES, Andrew Tomaras, VP and Director of Microbiology, BacterioScan Inc.
  • PHARMACOKINETIC AND PHARMACODYNAMIC APPROACHES TO OPTIMIZE DRUG DEVELOPMENT IN INVASIVE ASPERGILLOSIS, Laura Kovanda, Senior Director Global Development Project Leader, Astellas Pharma Global Development, Inc.

Attendees from across the world. Nations confirmed to attend include: Canada, Denmark, France, United Kingdom and the USA.

Over 18 key presentations from a mix of host nation government bodies, big pharma and biotechs such as the UNIT System College of Pharmacy, Janssen, Octagon Therapeutics, Achaogen, Agile Sciences, Venatorx Pharmaceuticals, Tetraphase Pharmaceuticals, Motif BioSciences, MedImmune, Case Western Reserve University, SCYNEXIS, Healthcare Business of Merck, Seres Therapeutics and more.

New interviews and expert insight from those at forefront of therapeutic development and new initiatives. Includes Q&A’s with Octagon Therapeutics, Motif Bio, Astellas Pharma Global, Venatorx Pharmaceuticals and HHS/ASPR/BARDA.

Read them here

Global Biodefense is an official media partner of Superbugs & Superdrugs USA

Tags: ASPREmerging ThreatsEventsHHS

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC